Special Investigation in Patients With Rheumatoid Arthritis (Combo Study : Adalimumab With High Dose MTX)

Trial Profile

Special Investigation in Patients With Rheumatoid Arthritis (Combo Study : Adalimumab With High Dose MTX)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Adalimumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms Combo; HAWK
  • Sponsors Abbott Japan; AbbVie
  • Most Recent Events

    • 17 Jul 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
    • 17 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
    • 17 Jun 2017 Results (n=346, as of 15 Apr 2016, week 52) assessing long-term safety and effectiveness of adalimumab with higher-dose methotrexate, presented at the 18th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top